Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2014-11-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the progress of a major asset restructuring. It mentions stock suspension due to the planning of a significant asset reorganization, ongoing due diligence, audit, and evaluation work by intermediaries, and the continuation of stock suspension until the board approves and announces the restructuring plan. The document is short (772 characters) and serves as a progress update on a capital restructuring event rather than the actual restructuring report or financial statements. This fits the category of Capital/Financing Update (CAP) as it relates to fundraising or capital structure changes and is an update on the process rather than a final report or announcement of voting results.
2014-11-16 Chinese
关于第二届董事会第十九次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the resolution passed at the 19th meeting of the second board of directors held on November 14, 2014. It details the board meeting attendance, the agenda, and the unanimous approval of a proposal related to planning a major asset restructuring. The document does not contain financial statements or detailed financial analysis but is an official announcement of a board decision. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting result announcement. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1027 characters), and it is not merely announcing the publication of a report but is itself the announcement of a board resolution. Therefore, the correct classification is MANG with high confidence.
2014-11-16 Chinese
关于筹划重大资产重组的停牌公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the suspension of trading due to planning a major asset restructuring. It details the suspension period, conditions for resumption, and commitments related to the restructuring plan disclosure. There is no financial data, earnings information, or detailed report content. The document is an announcement about a capital restructuring event and trading suspension, not the restructuring plan or report itself. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on the announcement of the event, not a full report or filing.
2014-11-10 Chinese
独立董事关于关于使用自有资金进行银行结构性存款的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement of independent directors providing their opinion on the company's use of own funds for bank structured deposits. It references compliance with stock exchange rules and company bylaws, and it is signed by independent directors. The document is short (574 characters) and does not contain financial statements or detailed financial data. It is an opinion or certification related to a specific corporate action rather than a full report or announcement of financial results. This fits best under Regulatory Filings (RNS), which covers attestations, confirmations, and miscellaneous regulatory documents that do not fit other categories.
2014-10-27 Chinese
国信证券股份有限公司关于公司以募集资金置换预先投入募集资金投资项目的自筹资金的核查意见
Regulatory Filings
2014-10-27 Chinese
第二届董事会第十八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the second board of directors of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes details about the meeting date, voting results, and decisions such as the use of funds and approval to release the third quarter financial report. The document does not contain the financial report itself but mentions that the 2014 third quarter financial report will be released externally and is available on the designated disclosure website. The document length is short (1629 characters) and serves as a meeting resolution announcement rather than a full financial report. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2014-10-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.